Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of…
Federal Information & News Dispatch, Inc. |
Joint Meeting of the
Notice.
Citation: "79 FR 42338"
Document Number: "Docket No.
"Notices"
This notice announces a forthcoming meeting of a public advisory committee of the
Name of Committees:
General Function of the Committees: To provide advice and recommendations to the
Date and Time: The meeting will be held on
Location:
Contact Person:
Agenda: The committees will discuss new drug application (NDA) 206089 (oral testosterone undecanoate tablets), submitted by
FDA intends to make background material available to the public no later than 2 business days before the meeting. If
Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before
Persons attending
FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact
FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).
Dated:
Assistant Commissioner for Policy.
[FR Doc. 2014-17081 Filed 7-18-14;
BILLING CODE 4164-01-P
Copyright: | (c) 2014 Federal Information & News Dispatch, Inc. |
Wordcount: | 675 |
Mortgage and Loan Insurance Programs Under the National Housing Act–Debenture Interest Rates
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News